{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "UCHL1",
        "Protein_Change": {
          "ref": "Leu",
          "alt": "Ser",
          "position": "32"
        },
        "variant_string_id": "UCHL1 L32S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "UCH-L1 is secreted from neurons via an unconventional pathway, and the hydrolase activity is not necessary for this secretion. The ubiquitin binding activity and the sequence between Leu-32 and Leu-39 are involved in the secretion.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states the key findings regarding the unconventional secretion pathway and the role of the Leu-32 to Leu-39 sequence."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Treatment with Brefeldin A, an inhibitor of vesicle transport from the endoplasmic reticulum to the Golgi, did not block the secretion of UCH-L1, indicating that UCH-L1 is secreted by an unconventional pathway.",
          "judgment": "Yes",
          "reasoning": "The assay (Brefeldin A inhibition) is a broadly accepted method to investigate intracellular trafficking, specifically focusing on ER-Golgi transport.",
          "next_step_or_outcome": "Proceed to Step 3"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The findings regarding the unconventional secretion pathway and the involvement of the Leu-32 to Leu-39 sequence, coupled with the use of a broadly accepted assay (Brefeldin A), provide supporting evidence for a pathogenic role for this variant in Parkinson's disease."
    },
    {
      "variant_id": {
        "Gene": "UCHL1",
        "Protein_Change": {
          "ref": "Leu",
          "alt": "Ser",
          "position": "34"
        },
        "variant_string_id": "UCHL1 L34S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "UCH-L1 is secreted from neurons via an unconventional pathway, and the hydrolase activity is not necessary for this secretion. The ubiquitin binding activity and the sequence between Leu-32 and Leu-39 are involved in the secretion.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states the key findings regarding the unconventional secretion pathway and the role of the Leu-32 to Leu-39 sequence."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Treatment with Brefeldin A, an inhibitor of vesicle transport from the endoplasmic reticulum to the Golgi, did not block the secretion of UCH-L1, indicating that UCH-L1 is secreted by an unconventional pathway.",
          "judgment": "Yes",
          "reasoning": "The assay (Brefeldin A inhibition) is a broadly accepted method to investigate intracellular trafficking, specifically focusing on ER-Golgi transport.",
          "next_step_or_outcome": "Proceed to Step 3"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The findings regarding the unconventional secretion pathway and the involvement of the Leu-32 to Leu-39 sequence, coupled with the use of a broadly accepted assay (Brefeldin A inhibition), provide supporting evidence for a pathogenic role for this variant in Parkinson's disease."
    },
    {
      "variant_id": {
        "Gene": "UCHL1",
        "Protein_Change": {
          "ref": "Leu",
          "alt": "Ser",
          "position": "39"
        },
        "variant_string_id": "UCHL1 L39S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "UCH-L1 is secreted from neurons via an unconventional pathway, and the hydrolase activity is not necessary for this secretion. The ubiquitin binding activity and the sequence between Leu-32 and Leu-39 are involved in the secretion.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states the key findings regarding the unconventional secretion pathway and the role of the Leu-32 to Leu-39 sequence."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Treatment with Brefeldin A, an inhibitor of vesicle transport from the endoplasmic reticulum to the Golgi, did not block the secretion of UCH-L1, indicating that UCH-L1 is secreted by an unconventional pathway.",
          "judgment": "Yes",
          "reasoning": "The assay (Brefeldin A inhibition) is a broadly accepted method to investigate intracellular trafficking, specifically focusing on ER-Golgi transport.",
          "next_step_or_outcome": "Proceed to Step 3"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The findings regarding the unconventional secretion pathway and the involvement of the Leu-32 to Leu-39 sequence, coupled with the use of a broadly accepted assay (Brefeldin A inhibition), provide supporting evidence for a pathogenic role for this variant in Parkinson's disease."
    }
  ]
}